ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Biogen Acquires Hemophilia Drug Firm

January 8, 2007 | APPEARED IN VOLUME 85, ISSUE 2

Biogen Idec will acquire Syntonix Pharmaceuticals, a private biopharmaceutical firm with several preclinical programs in hemophilia. Syntonix also has drug delivery technologies that harness the body's natural pathways to protect antibodies against premature destruction and that transport antibodies across cell barriers. Biogen Idec will pay Syntonix' owners $40 million up front and could make additional payments of up to $80 million upon achievement of development milestones.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment